3.5
Biyoyararlanım: Genel Bakış
Biyoyararlanım, uygulanmadan sonra sistemik dolaşıma giren ve istenen etki bölgesine dağıtılabilen, değiştirilmemiş bir ilacın oranını ifade eder. Gas…
Bir ilaç uygulandıktan sonra, sistemik dolaşıma giren ve etki bölgesine dağıtılmak üzere mevcut olan uygulanan ilaç miktarına biyoyararlanım denir.
Oral yoldan uygulanan bir ilacın biyoyararlanımı, karaciğer tarafından GI emilimi ve biyotransformasyonundan etkilenir.
İntravenöz olarak uygulanan bir ilaç söz konusu olduğunda, ilaç doğrudan sistemik dolaşıma girer ve biyoyararlanımın tanım gereği% 100 olduğu varsayılır.
Oral yoldan uygulanan bir ilaç için, IV yolu yoluyla uygulanan ilacın plazma konsantrasyonunun karşılaştırılması, o ilacın biyoyararlanımının belirlenmesine yardımcı olur.
Hem oral hem de intravenöz olarak eşdeğer dozlarda uygulanan aynı ilaç için ilacın plazma konsantrasyonunun zamana karşı bir grafiği oluşturulabilir.
Her bir uygulama yolu için eğrinin altındaki toplam alan, o yol için ilaç emiliminin derecesini temsil eder.
Hesaplanan alanların oranı, oral yoldan uygulanan ilacın biyolojik olarak kullanılabilir fraksiyonunun bir tahminini verir.
View the full transcript and gain access to JoVE Core videos
Q1: What is bioavailability and why does it matter in pharmacology?
Bioavailability is the proportion of an administered drug that enters the systemic circulation and becomes available for distribution to its site of action. It determines how much of a drug dose actually reaches the bloodstream to produce therapeutic effects. Understanding bioavailability is essential for predicting drug efficacy and establishing appropriate dosing regimens.
Q2: Why is intravenous drug administration considered 100% bioavailable?
Intravenous administration delivers the drug directly into the systemic circulation, bypassing absorption barriers. Since the entire dose immediately enters the bloodstream without loss or metabolism before reaching circulation, its bioavailability is defined as 100% by convention, serving as the reference standard for comparing other routes.
Q3: What factors reduce bioavailability when drugs are taken orally?
Oral bioavailability is reduced by two primary factors: gastrointestinal absorption, which determines how much drug crosses the GI barrier, and liver biotransformation, which metabolizes the drug before it reaches systemic circulation. These processes collectively limit the amount of active drug available in the bloodstream compared to intravenous administration.
Q4: How is the bioavailability of an oral drug calculated?
Bioavailability is determined by comparing plasma concentration-time curves for the same drug given orally and intravenously at equivalent doses. The area under each curve represents drug absorption for that route. The ratio of the oral area to the intravenous area yields the bioavailable fraction, expressed as a percentage of the intravenous dose.
Q5: What does the area under the curve represent in bioavailability studies?
The area under the plasma concentration-time curve represents the total extent of drug absorption for a given route of administration. A larger area indicates greater drug absorption and systemic exposure. Comparing areas between oral and intravenous routes allows quantification of how much drug actually becomes bioavailable through each administration method.
Q6: How do oral and intravenous routes differ in their bioavailability profiles?
Intravenous administration achieves 100% bioavailability immediately, while oral administration typically yields lower bioavailability due to incomplete gastrointestinal absorption and hepatic metabolism. Plotting plasma concentration versus time for both routes reveals these differences: intravenous shows rapid peak concentration, while oral shows delayed absorption and lower peak levels.
Q7: Why is bioavailability comparison important for drug development?
Bioavailability comparison ensures drugs are formulated and dosed appropriately to achieve therapeutic effects. By quantifying how much drug reaches systemic circulation via different routes, developers can optimize formulations, predict clinical outcomes, and establish rational dosing strategies that account for absorption and metabolism losses.